• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

合并抗氨酰tRNA合成酶抗体的抗MDA5阳性皮肌炎的临床特征及预后

Clinical features and prognosis of anti-MDA5-positive dermatomyositis with coexistent anti-aminoacyl-tRNA synthetase antibodies.

作者信息

Wang Gang, Yan Dong, Weng Chenghua, Xue Leixi, Liu Zhichun

机构信息

Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

出版信息

Clin Rheumatol. 2025 Feb;44(2):767-774. doi: 10.1007/s10067-024-07298-4. Epub 2025 Jan 3.

DOI:10.1007/s10067-024-07298-4
PMID:39751977
Abstract

OBJECTIVES

This study aimed to evaluate the incidence and clinical significance of coexistence of anti-aminoacyl-tRNA synthetase (anti-ARS) antibody in patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5 + DM).

METHODS

We assessed a cohort of 246 consecutive patients with anti-MDA5 + DM. Clinical characteristics and survival rates were compared between patients with and without anti-ARS antibodies.

RESULTS

Of these 246 patients, 15 (15/246, 6.1%) were positive for anti-ARS antibodies. The anti-ARS-positive group had a higher proportion of mechanic's hands (53.3% vs 25.5%, P = 0.019), and the positivity rates for antinuclear antibody (ANA) (80.0% vs 50.6%, P = 0.033) and anti-Ro52 antibodies (93.3% vs 62.3%, P = 0.013) were also higher. However, the CRP levels were comparatively low [4.0 (0.5, 7.8) vs 6.0 (3.1, 12.2), P = 0.019]. In the overall population, no difference in survival rates was observed between anti-MDA5 + DM patients with or without anti-ARS antibodies (log-rank P = 0.339). The multivariate Cox regression analysis revealed that elevated lactate dehydrogenase (LDH) levels and the presence of rapidly progressive interstitial lung disease (RPILD) were associated with poor prognosis [hazard ratios of 1.002 (95% CI 1.001, 1.002, P < 0.001) and 11.096 (95% CI 5.006, 24.598, P < 0.001), respectively].

CONCLUSION

Among the 246 patients with anti-MDA5 + DM, only 15 patients (6.1%) tested positive for anti-ARS antibodies. The presence of anti-ARS antibodies is associated with the occurrence of mechanic's hands, as well as an increased positive rate of ANA and anti-Ro52 antibodies. Elevated LDH levels and the presence of RPILD are poor prognostic risk factors for patients with anti-MDA5 + DM. Key Points • The presence of anti-ARS antibodies is associated with the occurrence of mechanic's hands, as well as an increased positive rate of ANA and anti-Ro52 antibodies. • Elevated LDH levels and the presence of RPILD are poor prognostic risk factors for patients with anti-MDA5 + DM. • Understanding the clinical characteristics of these patients will help clinicians to develop individualised treatment plans for each patient.

摘要

目的

本研究旨在评估抗黑色素瘤分化相关基因5阳性皮肌炎(抗MDA5+DM)患者中抗氨酰tRNA合成酶(抗ARS)抗体共存的发生率及其临床意义。

方法

我们评估了连续246例抗MDA5+DM患者的队列。比较了有和没有抗ARS抗体患者的临床特征和生存率。

结果

在这246例患者中,15例(15/246,6.1%)抗ARS抗体呈阳性。抗ARS阳性组中技工手的比例更高(53.3%对25.5%,P=0.019),抗核抗体(ANA)(80.0%对50.6%,P=0.033)和抗Ro52抗体的阳性率(93.3%对62.3%,P=0.013)也更高。然而,CRP水平相对较低[4.0(0.5,7.8)对6.0(3.1,12.2),P=0.019]。在总体人群中,有或没有抗ARS抗体的抗MDA5+DM患者的生存率没有差异(对数秩检验P=0.339)。多因素Cox回归分析显示,乳酸脱氢酶(LDH)水平升高和快速进展性间质性肺病(RPILD)的存在与预后不良相关[风险比分别为1.002(95%CI 1.001,1.002,P<0.001)和11.096(95%CI 5.006,24.598,P<0.001)]。

结论

在246例抗MDA5+DM患者中,只有15例(6.1%)抗ARS抗体检测呈阳性。抗ARS抗体的存在与技工手的发生以及ANA和抗Ro52抗体阳性率增加有关。LDH水平升高和RPILD的存在是抗MDA5+DM患者预后不良的危险因素。要点•抗ARS抗体的存在与技工手的发生以及ANA和抗Ro52抗体阳性率增加有关。•LDH水平升高和RPILD的存在是抗MDA5+DM患者预后不良的危险因素。•了解这些患者的临床特征将有助于临床医生为每位患者制定个体化的治疗方案。

相似文献

1
Clinical features and prognosis of anti-MDA5-positive dermatomyositis with coexistent anti-aminoacyl-tRNA synthetase antibodies.合并抗氨酰tRNA合成酶抗体的抗MDA5阳性皮肌炎的临床特征及预后
Clin Rheumatol. 2025 Feb;44(2):767-774. doi: 10.1007/s10067-024-07298-4. Epub 2025 Jan 3.
2
Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.多发性肌炎/皮肌炎相关间质性肺疾病中肌炎特异性自身抗体的综合评估
Respir Med. 2016 Dec;121:91-99. doi: 10.1016/j.rmed.2016.10.019. Epub 2016 Nov 2.
3
Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis.日本多发性肌炎/皮肌炎患者肌炎特异性自身抗体谱的临床意义
Medicine (Baltimore). 2019 May;98(20):e15578. doi: 10.1097/MD.0000000000015578.
4
Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody.根据自身抗体比较皮肌炎合并间质性肺炎的长期预后和复发情况:抗氨酰tRNA合成酶抗体与抗黑色素瘤分化相关基因5抗体的比较
Rheumatol Int. 2017 Aug;37(8):1335-1340. doi: 10.1007/s00296-017-3729-y. Epub 2017 Apr 27.
5
Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.抗 MDA5 抗体阳性皮肌炎相关间质性肺病患者血清几丁质酶水平的临床意义。
J Rheumatol. 2019 Aug;46(8):935-942. doi: 10.3899/jrheum.180825. Epub 2019 May 15.
6
Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.抗氨酰基转移RNA合成酶抗体及抗黑色素瘤分化相关基因5抗体与多发性肌炎/皮肌炎相关间质性肺疾病治疗反应的相关性
Respir Investig. 2017 Jan;55(1):24-32. doi: 10.1016/j.resinv.2016.08.007. Epub 2016 Sep 30.
7
The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients.抗 MDA5 和抗氨酰-tRNA 合成酶抗体双阳性皮肌炎患者的临床特征和预后。
Front Immunol. 2022 Aug 30;13:987841. doi: 10.3389/fimmu.2022.987841. eCollection 2022.
8
Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.抗 MDA5 阳性伴间质性肺病的无肌病性皮肌炎中抗 Ro52 抗体的预后价值。
Rheumatology (Oxford). 2021 Jul 1;60(7):3343-3351. doi: 10.1093/rheumatology/keaa786.
9
The comparison of nailfold videocapillaroscopy findings between anti-melanoma differentiation-associated gene 5 antibody and anti-aminoacyl tRNA synthetase antibody in patients with dermatomyositis complicated by interstitial lung disease.抗黑色素瘤分化相关基因 5 抗体与抗氨酰基 tRNA 合成酶抗体阳性的皮肌炎合并间质性肺病患者甲襞微循环的比较。
Sci Rep. 2020 Sep 24;10(1):15692. doi: 10.1038/s41598-020-72752-7.
10
The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients.抗 MDA5 抗体阳性皮肌炎患者 1 型 IFN 与血管病变的关系。
Rheumatology (Oxford). 2019 May 1;58(5):786-791. doi: 10.1093/rheumatology/key386.

本文引用的文献

1
Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model.抗 MDA5 阳性皮肌炎快速进展性间质性肺病风险预测:CROSS 模型。
Front Immunol. 2024 Feb 1;15:1286973. doi: 10.3389/fimmu.2024.1286973. eCollection 2024.
2
Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress.抗 MDA5 抗体阳性皮肌炎:发病机制与临床进展。
Nat Rev Rheumatol. 2024 Jan;20(1):48-62. doi: 10.1038/s41584-023-01054-9. Epub 2023 Dec 6.
3
Gender differences in patients with anti-MDA5-positive dermatomyositis: a cohort study of 251 cases.
抗 MDA5 阳性皮肌炎患者的性别差异:251 例队列研究。
Clin Rheumatol. 2024 Jan;43(1):339-347. doi: 10.1007/s10067-023-06816-0. Epub 2023 Nov 21.
4
Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: A meta-analysis and systematic review.抗 MDA5 抗体阳性皮肌炎患者死亡的风险因素:荟萃分析和系统评价。
Semin Arthritis Rheum. 2023 Oct;62:152231. doi: 10.1016/j.semarthrit.2023.152231. Epub 2023 Jun 9.
5
The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients.抗 MDA5 和抗氨酰-tRNA 合成酶抗体双阳性皮肌炎患者的临床特征和预后。
Front Immunol. 2022 Aug 30;13:987841. doi: 10.3389/fimmu.2022.987841. eCollection 2022.
6
Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis.中性粒细胞与淋巴细胞比值是抗 MDA5 阳性皮肌炎的预测标志物。
BMC Pulm Med. 2022 Aug 17;22(1):316. doi: 10.1186/s12890-022-02106-8.
7
Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk.抗MDA5抗体阳性皮肌炎中抗Ro52抗体的共存与快速进展性间质性肺病及死亡风险高度相关。
J Rheumatol. 2023 Feb;50(2):219-226. doi: 10.3899/jrheum.220139. Epub 2022 Jun 15.
8
Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.抗 MDA5 阳性皮肌炎中的间质性肺病。
Clin Rev Allergy Immunol. 2021 Apr;60(2):293-304. doi: 10.1007/s12016-020-08822-5. Epub 2021 Jan 6.
9
Mortality Risk Prediction in Amyopathic Dermatomyositis Associated With Interstitial Lung Disease: The FLAIR Model.无肌病性皮肌炎相关间质性肺病患者的死亡率预测:FLAIR 模型。
Chest. 2020 Oct;158(4):1535-1545. doi: 10.1016/j.chest.2020.04.057. Epub 2020 May 16.
10
Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis.皮肌炎患者肌炎特异性和肌炎相关性自身抗体的现有认识和最新进展。
Expert Rev Clin Immunol. 2020 Jan;16(1):79-89. doi: 10.1080/1744666X.2019.1699059. Epub 2019 Dec 8.